Items where Author is "Croft, SL"
Up a level |
Number of items: 34.
Bibliographic data only
Burza, S;
Croft, SL;
Boelaert, M;
(2018)
Leishmaniasis.
Elsevier.
DOI: https://doi.org/10.1016/S0140-6736(18)31204-2
Full text not available from this repository.
Croft, SL;
Buffett, P;
(2015)
Leishmaniasis.
In: Goldman, L; Schafer, AI, (eds.)
Goldman’s Cecil Medicine, 25th ed.
Elsevier-Saunders, pp. 2120-2025.
http://researchonline.lshtm.ac.uk/id/eprint/2950079
Full text not available from this repository.
Croft, SL;
Olliaro, P;
(2011)
Leishmaniasis chemotherapy-challenges and opportunities.
Clinical microbiology and infection, 17 (10).
pp. 1478-83.
ISSN 1198-743X
DOI: https://doi.org/10.1111/j.1469-0691.2011.03630.x
Full text not available from this repository.
Croft, SL;
Ward, S;
(2015)
The Nobel Prize in Medicine 2015: Two drugs that changed global health.
Science translational medicine, 7 (316).
316ed14.
ISSN 1946-6234
DOI: https://doi.org/10.1126/scitranslmed.aad5868
Full text not available from this repository.
Das, S;
Freier, A;
Boussoffara, T;
Das, S;
Oswald, D;
Losch, FO;
Selka, M;
Sacerdoti-Sierra, N;
Schönian, G;
Wiesmüller, KH;
+10 more...
Seifert, K;
Schroff, M;
Juhls, C;
Jaffe, CL;
Roy, S;
Das, P;
Louzir, H;
Croft, SL;
Modabber, F;
Walden, P;
(2014)
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.
Science translational medicine, 6 (234).
234ra56.
ISSN 1946-6234
DOI: https://doi.org/10.1126/scitranslmed.3008222
Full text not available from this repository.
Lamour, SD;
Veselkov, KA;
Posma, JM;
Giraud, E;
Rogers, ME;
Croft, S;
Marchesi, JR;
Holmes, E;
Seifert, K;
Saric, J;
(2014)
Metabolic, Immune, and Gut Microbial Signals Mount a Systems Response to Leishmania major Infection.
Journal of proteome research, 14 (1).
pp. 318-329.
ISSN 1535-3893
DOI: https://doi.org/10.1021/pr5008202
Full text not available from this repository.
Laurent, T;
Rijal, S;
Yardley, V;
Croft, S;
De Doncker, S;
Decuypere, S;
Khanal, B;
Singh, R;
Schönian, G;
Kuhls, K;
+2 more...
Chappuis, F;
Dujardin, JC;
(2006)
Epidemiological dynamics of antimonial resistance in Leishmania donovani: Genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal.
Infection, genetics and evolution, 7 (2).
pp. 206-12.
ISSN 1567-1348
DOI: https://doi.org/10.1016/j.meegid.2006.08.005
Full text not available from this repository.
Perez-Victoria, FJ;
Sanchez-Canete, MP;
Seifert, K;
Croft, SL;
Sundar, S;
Castanys, S;
Gamarro, F;
(2006)
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
Drug resistance updates, 9 (1-2).
pp. 26-39.
ISSN 1368-7646
DOI: https://doi.org/10.1016/j.drup.2006.04.001
Full text not available from this repository.
Sanderson, L;
Yardley, V;
Croft, SL;
(2014)
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
The Journal of antimicrobial chemotherapy.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dku069
Full text not available from this repository.
Seifert, K;
Juhls, C;
Salguero, FJ;
Croft, SL;
(2015)
Sequential chemo-immunotherapy of experimental visceral leishmaniasis using single low dose liposomal amphotericin B and a novel DNA vaccine candidate.
Antimicrobial agents and chemotherapy, 59 (9).
pp. 5819-23.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00273-15
Full text not available from this repository.
Van Bocxlaer, K;
Yardley, V;
Murdan, S;
Croft, SL;
(2016)
Drug permeation and barrier damage in Leishmania-infected mouse skin.
The Journal of antimicrobial chemotherapy, 71 (6).
pp. 1578-85.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dkw012
Full text not available from this repository.
Xu, J;
Bergquist, R;
Qian, YJ;
Wang, Q;
Yu, Q;
Peeling, R;
Croft, S;
Guo, JG;
Zhou, XN;
(2016)
China-Africa and China-Asia Collaboration on Schistosomiasis Control: A SWOT Analysis.
Adv Parasitol, 92.
pp. 435-66.
ISSN 2163-6079
DOI: https://doi.org/10.1016/bs.apar.2016.02.005
Full text not available from this repository.
Public
Baker, DA;
Stewart, LB;
Large, JM;
Bowyer, PW;
Ansell, KH;
Jiménez-Díaz, MB;
El Bakkouri, M;
Birchall, K;
Dechering, KJ;
Bouloc, NS;
+19 more...
Coombs, PJ;
Whalley, D;
Harding, DJ;
Smiljanic-Hurley, E;
Wheldon, MC;
Walker, EM;
Dessens, JT;
Lafuente, MJ;
Sanz, LM;
Gamo, FJ;
Ferrer, SB;
Hui, R;
Bousema, T;
Angulo-Barturén, I;
Merritt, AT;
Croft, SL;
Gutteridge, WE;
Kettleborough, CA;
Osborne, SA;
(2017)
A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.
Nature communications, 8 (1).
p. 430.
ISSN 2041-1723
DOI: https://doi.org/10.1038/s41467-017-00572-x
Barrett, MP;
Croft, SL;
(2014)
Emerging paradigms in anti-infective drug design.
Parasitology, 141 (1).
pp. 1-7.
ISSN 0031-1820
DOI: https://doi.org/10.1017/S0031182013001224
Basilico, N;
Parapini, S;
Sparatore, A;
Romeo, S;
Misiano, P;
Vivas, L;
Yardley, V;
Croft, SL;
Habluetzel, A;
Lucantoni, L;
+8 more...
Renia, L;
Russell, B;
Suwanarusk, R;
Nosten, F;
Dondio, G;
Bigogno, C;
Jabes, D;
Taramelli, D;
(2017)
In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial.
Molecules (Basel, Switzerland), 22 (12).
ISSN 1420-3049
DOI: https://doi.org/10.3390/molecules22122102
Burrell-Saward, H;
Harris, AJ;
de LaFlor, R;
Sallam, H;
Alavijeh, MS;
Ward, TH;
Croft, SL;
(2017)
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human african trypanosomiasis.
International journal of antimicrobial agents, 50 (2).
pp. 203-209.
ISSN 0924-8579
DOI: https://doi.org/10.1016/j.ijantimicag.2017.01.038
Burrell-Saward, H;
Rodgers, J;
Bradley, B;
Croft, SL;
Ward, TH;
(2014)
A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis.
The Journal of antimicrobial chemotherapy, 70 (2).
pp. 510-7.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dku393
Cameron, MM;
Acosta-Serrano, A;
Bern, C;
Boelaert, M;
den Boer, M;
Burza, S;
Chapman, LA;
Chaskopoulou, A;
Coleman, M;
Courtenay, O;
+21 more...
Croft, S;
Das, P;
Dilger, E;
Foster, G;
Garlapati, R;
Haines, L;
Harris, A;
Hemingway, J;
Hollingsworth, TD;
Jervis, S;
Medley, G;
Miles, M;
Paine, M;
Picado, A;
Poché, R;
Ready, P;
Rogers, M;
Rowland, M;
Sundar, S;
de Vlas, SJ;
Weetman, D;
(2016)
Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India.
Parasites & vectors, 9 (1).
p. 25.
ISSN 1756-3305
DOI: https://doi.org/10.1186/s13071-016-1309-8
Croft, SL;
(2017)
Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.
Parasitology.
pp. 1-11.
ISSN 0031-1820
DOI: https://doi.org/10.1017/S0031182017001664
Croft, SL;
(2016)
Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration.
Genome Biol, 17 (1).
p. 46.
ISSN 1474-760X
DOI: https://doi.org/10.1186/s13059-016-0916-1
Daunes, S;
Yardley, V;
Croft, SL;
D'Silva, C;
(2016)
Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesiense.
Bioorganic & medicinal chemistry.
ISSN 0968-0896
DOI: https://doi.org/10.1016/j.bmc.2016.12.016
Ganguly, NK;
Croft, S;
Singh, L;
Sinha, S;
Balganesh, T;
(2014)
Biomedicine and biotechnology: public health impact.
BioMed research international, 2014.
p. 524785.
ISSN 2314-6133
DOI: https://doi.org/10.1155/2014/524785
Hendrickx, S;
Guerin, PJ;
Caljon, G;
Croft, SL;
Maes, L;
(2016)
Evaluating drug resistance in visceral leishmaniasis: the challenges.
Parasitology, 145 (4).
pp. 453-463.
ISSN 0031-1820
DOI: https://doi.org/10.1017/S0031182016002031
Kaur, H;
Seifert, K;
Hawkes, GE;
Coumbarides, GS;
Alvar, J;
Croft, SL;
(2015)
Chemical and Bioassay Techniques to Authenticate Quality of the Anti-Leishmanial Drug Miltefosine.
The American journal of tropical medicine and hygiene, 92 (6 Supp).
pp. 31-8.
ISSN 0002-9637
DOI: https://doi.org/10.4269/ajtmh.14-0586
Riede, O;
Seifert, K;
Oswald, D;
Endmann, A;
Hock, C;
Winkler, A;
Salguero, FJ;
Schroff, M;
Croft, SL;
Juhls, C;
(2015)
Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.
Gene therapy, 22 (8).
pp. 628-35.
ISSN 0969-7128
DOI: https://doi.org/10.1038/gt.2015.35
Tegazzini, D;
Díaz, R;
Aguilar, F;
Peña, I;
Presa, JL;
Yardley, V;
Martin, JJ;
Coteron, JM;
Croft, SL;
Cantizani, J;
(2016)
A replicative in vitro assay for drug discovery against Leishmania donovani.
Antimicrobial agents and chemotherapy, 60 (6).
pp. 3524-32.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.01781-15
Van Bocxlaer, K;
Gaukel, E;
Hauser, D;
Park, SH;
Schock, S;
Yardley, V;
Randolph, R;
Plattner, JJ;
Merchant, T;
Croft, SL;
+2 more...
Jacobs, RT;
Wring, SA;
(2018)
Topical treatment for cutaneous leishmaniasis - dermato-pharmacokinetic led optimisation of benzoxaboroles.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.02419-17
Van Bocxlaer, K;
Yardley, V;
Murdan, S;
Croft, SL;
(2016)
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
The Journal of pharmacy and pharmacology, 68 (7).
pp. 862-72.
ISSN 0022-3573
DOI: https://doi.org/10.1111/jphp.12548
Voak, AA;
Harris, A;
Qaiser, Z;
Croft, SL;
Seifert, K;
(2017)
Treatment of experimental visceral leishmaniasis with single-dose liposomal amphotericin B - pharmacodynamics and biodistribution at different stages of disease.
Antimicrobial agents and chemotherapy, 61 (9).
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00497-17
Voak, AA;
Standing, JF;
Sepúlveda, N;
Harris, A;
Croft, SL;
Seifert, K;
(2018)
Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.
The Journal of antimicrobial chemotherapy.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dky014
Wijnant, GJ;
Van Bocxlaer, K;
Fortes Francisco, A;
Yardley, V;
Harris, A;
Alavijeh, M;
Murdan, S;
Croft, SL;
(2018)
Local skin inflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00631-18
Wijnant, GJ;
Van Bocxlaer, K;
Yardley, V;
Harris, A;
Alavijeh, M;
Silva-Pedrosa, R;
Antunes, S;
Mauricio, I;
Murdan, S;
Croft, SL;
(2018)
Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis.
International journal for parasitology Drugs and drug resistance, 8 (2).
pp. 223-228.
ISSN 2211-3207
DOI: https://doi.org/10.1016/j.ijpddr.2018.04.001
Wijnant, GJ;
Van Bocxlaer, K;
Yardley, V;
Harris, A;
Murdan, S;
Croft, SL;
(2017)
AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.02009-17
Wijnant, GJ;
Van Bocxlaer, K;
Yardley, V;
Murdan, S;
Croft, S;
(2017)
Efficacy of a Paromomycin plus Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00358-17